A Complete Response Induced by 21-day Sorafenib Therapy in a Patient with Advanced Hepatocellular Carcinoma
-
- Hagihara Atsushi
- Department of Hepatology, Osaka City University Hospital, Japan
-
- Teranishi Yuga
- Department of Hepatology, Osaka City University Hospital, Japan
-
- Kawamura Etsushi
- Department of Hepatology, Osaka City University Hospital, Japan
-
- Fujii Hideki
- Department of Hepatology, Osaka City University Hospital, Japan
-
- Iwai Shuji
- Department of Hepatology, Osaka City University Hospital, Japan
-
- Morikawa Hiroyasu
- Department of Hepatology, Osaka City University Hospital, Japan
-
- Enomoto Masaru
- Department of Hepatology, Osaka City University Hospital, Japan
-
- Tamori Akihiro
- Department of Hepatology, Osaka City University Hospital, Japan
-
- Kawada Norifumi
- Department of Hepatology, Osaka City University Hospital, Japan
この論文をさがす
抄録
The response rate and overall survival after sorafenib administration in patients with advanced hepatocellular carcinoma are unsatisfactory. We herein present the case of a 65-year-old man with multiple lung metastases of hepatocellular carcinoma. Because the patient had liver cirrhosis of Child-Pugh B accompanied by pancytopenia, sorafenib administration was initiated at a dose of 400 mg daily. Although he received sorafenib for only 21 days, the patient exhibited complete regression of the tumors. There was no clinical evidence of recurrence without the administration of anticancer treatment. It is unique that short-term sorafenib treatment achieved a complete response.<br>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 52 (14), 1589-1592, 2013
一般社団法人 日本内科学会